Home  »  Technologies   »  With 38.42% Distance From Low, Is C4 Therapeutics ...

With 38.42% Distance From Low, Is C4 Therapeutics Inc. (NASDAQ:CCCC) Still Renewed For Growth?

In last trading session, C4 Therapeutics Inc. (NASDAQ:CCCC) saw 0.37 million shares changing hands with its beta currently measuring 0. Company’s recent per share price level of $7.86 trading at -$1.52 or -16.20% at ring of the bell on the day assigns it a market valuation of $381.21M. That closing price of CCCC’s stock is at a discount of -401.53% from its 52-week high price of $39.42 and is indicating a premium of 38.42% from its 52-week low price of $4.84. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.46 million shares which gives us an average trading volume of 461.57K if we extend that period to 3-months.

For C4 Therapeutics Inc. (CCCC), analysts’ consensus is at an average recommendation of an Overweight while assigning it a mean rating of 2.50. Splitting up the data highlights that, out of 13 analysts covering the stock, 2 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 4 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -$0.67 in the current quarter.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored

C4 Therapeutics Inc. (NASDAQ:CCCC) trade information

Upright in the red during last session for losing -16.20%, in the last five days CCCC remained trading in the red while hitting it’s week-highest on Monday, 11/21/22 when the stock touched $7.86 price level, adding 21.48% to its value on the day. C4 Therapeutics Inc.’s shares saw a change of -75.59% in year-to-date performance and have moved -19.80% in past 5-day. C4 Therapeutics Inc. (NASDAQ:CCCC) showed a performance of -13.82% in past 30-days. Number of shares sold short was 4.94 million shares which calculate 8.38 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of $23.31 to the stock, which implies a rise of 66.28% to its current value. Analysts have been projecting $6.00 as a low price target for the stock while placing it at a high target of $84.00. It follows that stock’s current price would drop -968.7% in reaching the projected high whereas dropping to the targeted low would mean a gain of 23.66% for stock’s current value.

C4 Therapeutics Inc. (CCCC) estimates and forecasts

Statistics highlight that C4 Therapeutics Inc. is scoring comparatively lower than the scores of other players of the relevant industry. The company added 15.42% of value to its shares in past 6 months, showing an annual growth rate of -42.86% while that of industry is 4.60. Apart from that, the company came lowering its revenue forecast for fiscal year 2022. The company is estimating its revenue growth to decrease by -31.40% in the current quarter and calculating -129.00% decrease in the next quarter. This year revenue growth is estimated to fall -11.70% from the last financial year’s standing.

7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $9.07 million for the same. And 7 analysts are in estimates of company making revenue of $8.5 million in the next quarter that will end on Dec 2022.

CCCC Dividends

C4 Therapeutics Inc. is more likely to be releasing its next quarterly report between February 22 and February 27 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

C4 Therapeutics Inc. (NASDAQ:CCCC)’s Major holders

Insiders are in possession of 11.27% of company’s total shares while institution are holding 83.24 percent of that, with stock having share float percentage of 93.82%. Investors also watch the number of corporate investors in a company very closely, which is 83.24% institutions for C4 Therapeutics Inc. that are currently holding shares of the company. ArrowMark Colorado Holdings LLC is the top institutional holder at CCCC for having 5.84 million shares of worth $44.05 million. And as of Jun 29, 2022, it was holding 11.94% of the company’s outstanding shares.

The second largest institutional holder is Wasatch Advisors Inc, which was holding about 5.67 million shares on Jun 29, 2022. The number of shares represents firm’s hold over 11.58% of outstanding shares, having a total worth of $42.73 million.

On the other hand, Vanguard Explorer Fund, Inc. and Price (T.Rowe) New Horizons Fund are the top two Mutual Funds which own company’s shares. As of Jul 30, 2022, the former fund manager was holding 1.89 million shares of worth $18.24 million or 3.87% of the total outstanding shares. The later fund manager was in possession of 1.77 million shares on Jun 29, 2022, making its stake of worth around $13.34 million in the company or a holder of 3.62% of company’s stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

On Key

Related Posts

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]